United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt Sells 3,600 Shares

United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 3,600 shares of the business’s stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $325.45, for a total value of $1,171,620.00. Following the completion of the transaction, the chief executive officer now directly owns 130 shares in the company, valued at $42,308.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

United Therapeutics Stock Up 0.1 %

United Therapeutics stock traded up $0.27 during trading on Wednesday, hitting $322.23. 343,222 shares of the company were exchanged, compared to its average volume of 495,200. The business’s 50 day moving average is $310.44 and its 200 day moving average is $263.02. United Therapeutics Co. has a 52 week low of $208.62 and a 52 week high of $343.98. The company has a market capitalization of $14.29 billion, a P/E ratio of 15.22, a PEG ratio of 1.06 and a beta of 0.55. The company has a current ratio of 4.35, a quick ratio of 3.64 and a debt-to-equity ratio of 0.02.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $6.33 by ($0.48). The business had revenue of $714.90 million during the quarter, compared to the consensus estimate of $691.87 million. United Therapeutics had a net margin of 40.87% and a return on equity of 18.82%. The firm’s revenue for the quarter was up 19.8% compared to the same quarter last year. During the same quarter last year, the company earned $5.24 EPS. Analysts predict that United Therapeutics Co. will post 25.4 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. V Square Quantitative Management LLC bought a new position in United Therapeutics in the 2nd quarter valued at $30,000. Rise Advisors LLC purchased a new position in shares of United Therapeutics during the 1st quarter valued at $32,000. Innealta Capital LLC purchased a new position in shares of United Therapeutics during the 2nd quarter valued at $33,000. GAMMA Investing LLC purchased a new position in shares of United Therapeutics during the 4th quarter valued at $43,000. Finally, Benjamin F. Edwards & Company Inc. lifted its position in shares of United Therapeutics by 63.6% during the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 301 shares of the biotechnology company’s stock valued at $69,000 after buying an additional 117 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the company. The Goldman Sachs Group boosted their price target on United Therapeutics from $218.00 to $240.00 and gave the company a “neutral” rating in a research note on Friday, May 3rd. Oppenheimer boosted their price objective on United Therapeutics from $375.00 to $400.00 and gave the company an “outperform” rating in a report on Thursday, May 2nd. LADENBURG THALM/SH SH downgraded United Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 1st. UBS Group boosted their price objective on United Therapeutics from $300.00 to $370.00 and gave the company a “buy” rating in a report on Monday, July 8th. Finally, StockNews.com downgraded United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, August 2nd. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and ten have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $331.73.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.